Clinical cancer research : an official journal of the American Association for Cancer Research, 15 November 2015, Vol.21(22), pp.5030-6
Inhibitor of Apoptosis (IAP) proteins block programmed cell death and are expressed at high levels in various human cancers, thus making them attractive targets for cancer drug development. Second mitochondrial activator of caspases (Smac) mimetics are small-molecule inhibitors that mimic Smac, an endogenous antagonist of IAP proteins. Preclinical studies have shown that Smac mimetics can directly trigger cancer cell death or, even more importantly, sensitize tumor cells for various cytotoxic therapies, including conventional chemotherapy, radiotherapy, or novel agents. Currently, several Smac mimetics are under evaluation in early clinical trials as monotherapy or in rational combinations (i.e., GDC-0917/CUDC-427, LCL161, AT-406/Debio1143, HGS1029, and TL32711/birinapant). This review discusses the promise as well as some challenges at the translational interface of exploiting Smac mimetics as cancer therapeutics.
Antineoplastic Agents -- Therapeutic Use ; Apoptosis -- Drug Effects ; Intracellular Signaling Peptides and Proteins -- Therapeutic Use ; Mitochondrial Proteins -- Therapeutic Use ; Neoplasms -- Drug Therapy
View this record in MEDLINE/PubMed